These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7990448)

  • 41. Screening for drugs of abuse with the Roche ONTRAK assays.
    Armbruster DA; Krolak JM
    J Anal Toxicol; 1992; 16(3):172-5. PubMed ID: 1522711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening of several drugs of abuse in Italian workplace drug testing: performance comparisons of on-site screening tests and a fluorescence polarization immunoassay-based device.
    Basilicata P; Pieri M; Settembre V; Galdiero A; Della Casa E; Acampora A; Miraglia N
    Anal Chem; 2011 Nov; 83(22):8566-74. PubMed ID: 21992470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Setting cutoff concentrations for immunoassay screening of postmortem blood.
    Collison IB; Spiehler VR; Guluzian S; Sedgwick PR
    J Forensic Sci; 1998 Mar; 43(2):390-4. PubMed ID: 9544549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical evaluation of the Triage analytic device for drugs-of-abuse testing.
    de la Torre R; Domingo-Salvany A; Badia R; Gonzàlez G; McFarlane D; San L; Torrens M
    Clin Chem; 1996 Sep; 42(9):1433-8. PubMed ID: 8787700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of adulterating agents on FPIA analysis of urine for drugs of abuse.
    Schwarzhoff R; Cody JT
    J Anal Toxicol; 1993; 17(1):14-7. PubMed ID: 8429620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved screening for benzodiazepine metabolites in urine using the Triage Panel for Drugs of Abuse.
    Koch TR; Raglin RL; Kirk S; Bruni JF
    J Anal Toxicol; 1994; 18(3):168-72. PubMed ID: 7914948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of CEDIA and DRI Drugs of Abuse Immunoassays for Urine Screening on a Thermo Indiko Plus Analyzer.
    Köhler KM; Hammer R; Riedy K; Auwärter V; Neukamm MA
    J Clin Lab Anal; 2017 Jan; 31(1):. PubMed ID: 27346579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Online extraction LC-MS/MS method for the simultaneous quantitative confirmation of urine drugs of abuse and metabolites: amphetamines, opiates, cocaine, cannabis, benzodiazepines and methadone.
    de Jager AD; Bailey NL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2642-52. PubMed ID: 21839693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the NexScreen and DrugCheck Waive RT urine drug detection cups.
    Lin CN; Nelson GJ; McMillin GA
    J Anal Toxicol; 2013; 37(1):30-6. PubMed ID: 23144203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department.
    Johnson-Davis KL; Thompson CD; Clark CJ; McMillin GA; Lehman CM
    J Anal Toxicol; 2012 Jun; 36(5):345-8. PubMed ID: 22582270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of three commercial amphetamine immunoassays for detection of methamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, and methylenedioxyethylamphetamine.
    Ruangyuttikarn W; Moody DE
    J Anal Toxicol; 1988; 12(4):229-33. PubMed ID: 2903272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive Value of Positive Drug Screening Results in an Urban Outpatient Population.
    Bertholf RL; Sharma R; Reisfield GM
    J Anal Toxicol; 2016 Nov; 40(9):726-731. PubMed ID: 27550994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sweat testing in opioid users with a sweat patch.
    Kintz P; Tracqui A; Mangin P; Edel Y
    J Anal Toxicol; 1996 Oct; 20(6):393-7. PubMed ID: 8889674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Solid-phase extraction and HPLC-UV confirmation of drugs of abuse in urine.
    Ferrara SD; Tedeschi L; Frison G; Castagna F
    J Anal Toxicol; 1992; 16(4):217-22. PubMed ID: 1323732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of an automated microplate enzyme immunoassay for screening of postmortem blood for drugs of abuse.
    Spiehler VR; Collison IB; Sedgwick PR; Perez SL; Le SD; Farnin DA
    J Anal Toxicol; 1998; 22(7):573-9. PubMed ID: 9847007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent substance intake among patients admitted to acute psychiatric wards: physician's assessment and on-site urine testing compared with comprehensive laboratory analyses.
    Mordal J; Holm B; Mørland J; Bramness JG
    J Clin Psychopharmacol; 2010 Aug; 30(4):455-9. PubMed ID: 20631563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients.
    Pesce A; Rosenthal M; West R; West C; Crews B; Mikel C; Almazan P; Latyshev S
    Pain Physician; 2010; 13(3):273-81. PubMed ID: 20495592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Status of drugs-of-abuse testing in urine under blind conditions: an AACC study.
    Frings CS; Battaglia DJ; White RM
    Clin Chem; 1989 May; 35(5):891-4. PubMed ID: 2720992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urine drug testing for social service agencies in Nova Scotia, Canada.
    Fraser AD
    J Forensic Sci; 1998 Jan; 43(1):194-6. PubMed ID: 9456542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of an Automated Reader and Color Interpretation-Based Immunoassays for Multiplexed Drug-of-Abuse Testing in Urine.
    Kim SY; Kim H; Park Y; Lim J; Kim J; Koo SH; Kwon GC
    J Anal Toxicol; 2017 Jun; 41(5):412-420. PubMed ID: 28201761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.